Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy.
Ohba S, Teranishi T, Matsumura K, Kumon M, Kojima D, Fujiwara E, Nakao K, Kuwahara K, Murayama K, Pareira ES, Yamada S, Joko M, Nakae S, Muto J, Nishiyama Y, Adachi K, Sasaki H, Abe M, Hasegawa M, Hirose Y. Ohba S, et al. Among authors: pareira es. Sci Rep. 2025 Jan 11;15(1):1750. doi: 10.1038/s41598-025-85339-x. Sci Rep. 2025. PMID: 39799218 Free PMC article.
Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence.
Tamura R, Iwanami A, Ohara K, Nishimoto M, Pareira ES, Miwa T, Tsuzaki N, Kuranari Y, Morimoto Y, Toda M, Okano H, Nakamura M, Yoshida K, Sasaki H. Tamura R, et al. Among authors: pareira es. Brain Tumor Pathol. 2023 Apr;40(2):109-123. doi: 10.1007/s10014-023-00453-w. Epub 2023 Mar 9. Brain Tumor Pathol. 2023. PMID: 36892668
TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M, Yamaguchi S, Sasayama T, Tanaka S, Higuchi F, Iuchi T, Saito K, Kanamori M, Matsuda KI, Miyake Y, Tamura K, Tamai S, Nakamura T, Uda T, Okita Y, Fukai J, Sakamoto D, Hattori Y, Pareira ES, Hatae R, Ishi Y, Miyakita Y, Tanaka K, Takayanagi S, Otani R, Sakaida T, Kobayashi K, Saito R, Kurozumi K, Shofuda T, Nonaka M, Suzuki H, Shibuya M, Komori T, Sasaki H, Mizoguchi M, Kishima H, Nakada M, Sonoda Y, Tominaga T, Nagane M, Nishikawa R, Kanemura Y, Kuchiba A, Narita Y, Ichimura K. Arita H, et al. Among authors: pareira es. Acta Neuropathol Commun. 2020 Nov 23;8(1):201. doi: 10.1186/s40478-020-01078-2. Acta Neuropathol Commun. 2020. PMID: 33228806 Free PMC article.
Immunohistochemistry for O6-methylguanin-DNA methyltransferase in glioblastomas defined by WHO2016: Correlation with promoter methylation status and patients' progression-free survival with the cut-off value determined by ROC analysis.
Pareira ES, Kitano Y, Ohara K, Kanazawa T, Nakagawa Y, Yoshida K, Sasaki H. Pareira ES, et al. J Clin Neurosci. 2020 Mar;73:231-236. doi: 10.1016/j.jocn.2020.01.088. Epub 2020 Feb 16. J Clin Neurosci. 2020. PMID: 32070670